Genmab’s Tivdak wins Japan’s approval for advanced cervical cancer after a Phase 3 trial showed improved survival over chemotherapy.
Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer
Where Today's News Shapes Tomorrow
